These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 29610308

  • 1. Increased autophagy blocks HER2-mediated breast tumorigenesis.
    Vega-Rubín-de-Celis S, Zou Z, Fernández ÁF, Ci B, Kim M, Xiao G, Xie Y, Levine B.
    Proc Natl Acad Sci U S A; 2018 Apr 17; 115(16):4176-4181. PubMed ID: 29610308
    [Abstract] [Full Text] [Related]

  • 2. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.
    Breast Cancer Res; 2015 Jun 19; 17(1):86. PubMed ID: 26084280
    [Abstract] [Full Text] [Related]

  • 3. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov 19; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 4. Interaction between Her2 and Beclin-1 proteins underlies a new mechanism of reciprocal regulation.
    Han J, Hou W, Lu C, Goldstein LA, Stolz DB, Watkins SC, Rabinowich H.
    J Biol Chem; 2013 Jul 12; 288(28):20315-25. PubMed ID: 23703612
    [Abstract] [Full Text] [Related]

  • 5. HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
    Tracey N, Creedon H, Kemp AJ, Culley J, Muir M, Klinowska T, Brunton VG.
    Breast Cancer Res Treat; 2020 Feb 12; 179(3):543-555. PubMed ID: 31705351
    [Abstract] [Full Text] [Related]

  • 6. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M, Chakrabarti R, Kongara S, Price S, Nahar R, Lozy F, Zhong H, Vazquez A, Kang Y, Karantza V.
    Autophagy; 2014 Feb 12; 10(11):2036-52. PubMed ID: 25483966
    [Abstract] [Full Text] [Related]

  • 7. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID.
    J Cell Biochem; 2008 Feb 01; 103(2):624-35. PubMed ID: 17562544
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
    Zhu X, Wu L, Qiao H, Han T, Chen S, Liu X, Jiang R, Wei Y, Feng D, Zhang Y, Ma Y, Zhang S, Zhang J.
    J Cell Biochem; 2013 Dec 01; 114(12):2643-53. PubMed ID: 23794518
    [Abstract] [Full Text] [Related]

  • 10. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
    Yeh ES, Abt MA, Hill EG.
    Breast Cancer Res Treat; 2015 Jan 01; 149(1):91-8. PubMed ID: 25515931
    [Abstract] [Full Text] [Related]

  • 11. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):862-71. PubMed ID: 25449780
    [Abstract] [Full Text] [Related]

  • 12. ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss.
    Lozy F, Cai-McRae X, Teplova I, Price S, Reddy A, Bhanot G, Ganesan S, Vazquez A, Karantza V.
    Autophagy; 2014 Apr 28; 10(4):662-76. PubMed ID: 24492513
    [Abstract] [Full Text] [Related]

  • 13. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
    Chen S, Zhu X, Qiao H, Ye M, Lai X, Yu S, Ding L, Wen A, Zhang J.
    Tumour Biol; 2016 Feb 28; 37(2):2321-31. PubMed ID: 26369543
    [Abstract] [Full Text] [Related]

  • 14. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
    Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J.
    Oncogene; 2009 Feb 12; 28(6):803-14. PubMed ID: 19060928
    [Abstract] [Full Text] [Related]

  • 15. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
    Werfel TA, Wang S, Jackson MA, Kavanaugh TE, Joly MM, Lee LH, Hicks DJ, Sanchez V, Ericsson PG, Kilchrist KV, Dimobi SC, Sarett SM, Brantley-Sieders DM, Cook RS, Duvall CL.
    Cancer Res; 2018 Apr 01; 78(7):1845-1858. PubMed ID: 29358172
    [Abstract] [Full Text] [Related]

  • 16. Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma.
    Chen YJ, Chi CW, Su WC, Huang HL.
    Oncotarget; 2014 Jul 15; 5(13):4845-54. PubMed ID: 24947784
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.
    Huang WC, Hung CM, Wei CT, Chen TM, Chien PH, Pan HL, Lin YM, Chen YJ.
    Oncotarget; 2016 Sep 20; 7(38):62352-62363. PubMed ID: 27694691
    [Abstract] [Full Text] [Related]

  • 19. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK.
    Oncotarget; 2017 Apr 25; 8(17):28971-28989. PubMed ID: 28423644
    [Abstract] [Full Text] [Related]

  • 20. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.
    Oncogene; 2011 Sep 29; 30(39):4097-106. PubMed ID: 21499301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.